Join Medicilon at the 14th World ADC London 2024

World ADC London

Europe's Longest Standing & Definitive Antibody-Drug Conjugate Event！

Identify Novel Targets, Select the Optimal Combination Partner & Streamline CMC Strategy to Accelerate ADCs to Earlier-Line Treatments 

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. As of the end of 2023, Medicilon has successfully assisted in the clinical approval of 23 ADC drugs and has 20+ ADC projects under development.

Date: March 12-15, 2024
Location: London, UK
Medicilon Booth #26

Medicilon ADC R&D Service Platform

In the formulation of ADC preclinical integrated research plan, Medicilon has in-depth communication with customers. The backbone of scientific research has combined the characteristics of each case with years of practical experience and technical accumulation, and carefully submitted high-quality experimental plans and results to customers. Up to now, Medicilon has undertaken more than 100 major IND application biopharmaceutical projects, including monoclonal antibodies, double antibodies, polyclonal antibodies, ADCs, viral vaccines and fusion proteins. As of the end of 2023, Medicilon has successfully assisted in the clinical approval of 23 ADC drugs and has 20+ ADC projects under development.

Meet with Medicilon

Subject丨World ADC London

Company *

Name *

Work Email *

Title*

Verification Code